Abstract:Background Lung cancer is a common malignant carcinoma of respiratory system with high morbidity and mortality. Kelch-like epichlorohydrin-related protein 1 (Keap1), a member of the BTB-Kelch protein family, has been reported as an important molecule in several cancers. However, its potential role in tumor is still controversial. Here we aim to clarify the effect of Keap1 on the biological characteristics and chemotherapy resistance in lung adenocarcinoma (LUAD). Methods Immunohistochemistry was conducted to compare Keap1 expression in lung adenocarcinoma tissues and matched non-cancerous tissues, and the correlation between Keap1 expression and clinicopathological features was analyzed. Subsequently, the stable A549 and H1299 cell lines with Keap1 knockdown or overexpression were constructed using lentivirus. The roles of Keap1 on the cell proliferation, migration, invasion and drug resistance were investigated by colony formation assay, cell proliferation assay, wound scratch test, transwell invasion assay and drug sensitivity assay, respectively. Results Keap1 was lowly expressed in tumor tissues compared to matched non-cancerous tissues, and its expression was correlated with TNM stage and lymph node metastasis. Early stage (I) tumors without lymph node metastasis had higher levels of Keap1 expression compared with late-stage tumors (II, III) with the presence of lymphatic metastasis. Colony formation assays showed that Keap1 knockdown promoted the proliferation of A549 and H1299 cells, and the cell growth curves further confirmed this feature. In contrast, wound scratch and transwell invasion experiments showed that Keap1 overexpression inhibited cell migration and invasive malignancy. The IC50 for cisplatin and paclitaxel were significantly increased by Keap1 knockdown in A549 and H1299 cell lines. Conclusion Keap1 knockdown promotes tumor cell growth, proliferation, invasion, metastasis and chemotherapy resistance in LUAD. It may be a potential tumor marker to guide the staging and treatment of lung cancer.

Advances of protein kinase C and its inhibitors in drug resistance of lung cancer

[Research Progress on MKP-1 in Tumor Drug Resistance].

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma

Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer

Drug resistance mechanism and reversal strategy in lung cancer immunotherapy

Protein tyrosine phosphatases: emerging role in cancer therapy resistance

Inhibition of Kelch-like epichlorohydrin-related protein 1 promotes the progression and drug resistance of lung adenocarcinoma

Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

Research Progress in the Use of Combinations of Platinum-Based Chemotherapy and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Recent progress in targeted therapy for non-small cell lung cancer

Updates on altered signaling pathways in tumor drug resistance

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Drug resistance to targeted therapeutic strategies in non-small cell lung cancer

A protracted war against cancer drug resistance

Inhibition of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin Via Upregulation of PML

High prevalence of peripheral atherosclerosis in a rapidly developing country.

Pathological transition as the arising mechanism for drug resistance in lung cancer